Abstract
Introduction
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects.
Results and discussion
Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carella AM, Frassoni F, Melo J et al (1997) New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 82:478–495
Mahapatra M, Mishra P, Kumar R (2007) Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 86:537–538 doi:10.1007/s00277-007-0265-y
Breccia M, Carmosino I, Russo E et al (2005) Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 74:121–123 doi:10.1111/j.1600-0609.2004.00351.x
Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037 doi:10.1056/NEJM200104053441401
Severino G, Chillotti C, De Lisa R et al (2005) Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother 39:162–164 doi:10.1345/aph.1E127
O’Brien SG, Deininger MW (2003) Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 40(Suppl 2):26–30 doi:10.1016/S0037-1963(03)70017-1
van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423 doi:10.1016/S0140-6736(01)06535-7
Brouard M, Saurat JH (2001) Cutaneous reactions to STI571. N Engl J Med 345:618–619 doi:10.1056/NEJM200108233450814
Lim DS, Muir J (2002) Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology 205:169–171 doi:10.1159/000063899
Pascual JC, Matarredona J, Miralles J et al (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45:1471–1473 doi:10.1111/j.1365-4632.2006.03171.x
Chainani-Wu N, Lozada-Nur F, Terrault N (2004) Hepatitis C virus and lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:171–183 doi:10.1016/j.tripleo.2003.11.010
Cunha KS, Manso AC, Cardoso AS et al (2005) Prevalence of oral lichen planus in Brazilian patients with HCV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:330–333 doi:10.1016/j.tripleo.2004.11.017
Lodi G, Giuliani M, Majorana A et al (2004) Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 151:1172–1181 doi:10.1111/j.1365-2133.2004.06257.x
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Basso, F.G., Boer, C.C., Corrêa, M.E.P. et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer 17, 465–468 (2009). https://doi.org/10.1007/s00520-008-0536-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-008-0536-8